within Pharmacolibrary.Drugs.ATC.R;

model R03AL01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 1.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fenoterol and ipratropium bromide is a fixed-dose combination used as an inhaled bronchodilator in the management of chronic obstructive pulmonary disease (COPD) and asthma. Fenoterol is a beta2-adrenergic agonist that provides rapid bronchodilation and relief of bronchospasm, while ipratropium bromide is an anticholinergic agent that inhibits bronchoconstriction. The combination is widely approved and used for symptomatic relief and maintenance treatment in obstructive airway diseases.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are typical for healthy adults after inhalation of fenoterol (50 mcg) and ipratropium bromide (20 mcg) per dose; data estimated based on clinical summaries and individual compound data due to lack of direct published PK models for the combination.</p><h4>References</h4><ol><li><p>Goldberg, J, et al., &amp; Hinzmann, R (2001). Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler. <i>The European respiratory journal</i> 17(2) 225–232. DOI:<a href=&quot;https://doi.org/10.1183/09031936.01.17202250&quot;>10.1183/09031936.01.17202250</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11334124/&quot;>https://pubmed.ncbi.nlm.nih.gov/11334124</a></p></li><li><p>Rammeloo, RH, et al., &amp; Cornelissen, PJ (1992). Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease. <i>Respiration; international review of thoracic diseases</i> 59(6) 322–326. DOI:<a href=&quot;https://doi.org/10.1159/000196081&quot;>10.1159/000196081</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1488568/&quot;>https://pubmed.ncbi.nlm.nih.gov/1488568</a></p></li><li><p>Sano, F, et al., &amp; Naspitz, CK (2000). Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. <i>The Journal of allergy and clinical immunology</i> 105(4) 699–703. DOI:<a href=&quot;https://doi.org/10.1067/mai.2000.104784&quot;>10.1067/mai.2000.104784</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10756218/&quot;>https://pubmed.ncbi.nlm.nih.gov/10756218</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03AL01;
